#LamaBerjawi is presenting our results about #ferroptosis, #senescence and #epithelialovariancancer at #EACR2025 @udc.gal @cicaudc.bsky.social #INIBIC
June 18, 2025 at 1:03 PM
#LamaBerjawi is presenting our results about #ferroptosis, #senescence and #epithelialovariancancer at #EACR2025 @udc.gal @cicaudc.bsky.social #INIBIC
#oncology #resistantovariancancer #ovariancancer #mirvetuximabsoravtansine #Elahere #AbbVie #antibodydrugconjugate #ADC #epithelialovariancancer #fallopiantubecancer #primaryperitonealcancer #folatereceptoralphapositiveovariancancer #MIRASOLstudy #CancerDrugsFund
zurl.co/3c2Cw
zurl.co/3c2Cw
First new NHS treatment in over 20 years recommended for women with resistant ovarian cancer
NICE recommends new treatment for resistant ovarian cancer
www.nice.org.uk
June 5, 2026 at 9:06 AM
📣ESMO #ClinicalPracticeGuideline Express Update on #EpithelialOvarianCancer:
- Rucaparib: 1st-line PARPi maintenance option
- MIRV: for recurrent FRα-high #OvarianCancer after 1-3 prior therapies & PFI <6 months
🔗 https://ow.ly/J06u50Y4HT8
#GYNOnc #Oncology #ESMOGuidelines
- Rucaparib: 1st-line PARPi maintenance option
- MIRV: for recurrent FRα-high #OvarianCancer after 1-3 prior therapies & PFI <6 months
🔗 https://ow.ly/J06u50Y4HT8
#GYNOnc #Oncology #ESMOGuidelines
January 28, 2026 at 9:30 AM
📣ESMO #ClinicalPracticeGuideline Express Update on #EpithelialOvarianCancer:
- Rucaparib: 1st-line PARPi maintenance option
- MIRV: for recurrent FRα-high #OvarianCancer after 1-3 prior therapies & PFI <6 months
🔗 https://ow.ly/J06u50Y4HT8
#GYNOnc #Oncology #ESMOGuidelines
- Rucaparib: 1st-line PARPi maintenance option
- MIRV: for recurrent FRα-high #OvarianCancer after 1-3 prior therapies & PFI <6 months
🔗 https://ow.ly/J06u50Y4HT8
#GYNOnc #Oncology #ESMOGuidelines